ERYtech Pharma Announces Clinical Trial Authorizations In Finland And Spain For Its European Phase 2b Study In AML
1/15/2014 8:47:18 AM
ERYTECH Pharma (Paris:ERYP) (Euronext Paris: FR0011471135 - ERYP), a French biopharmaceutical company that develops innovative treatments for acute leukemia and other oncology indications with unmet medical needs, announces it received authorizations for its Phase IIb GRASPA-ML clinical trial in Acute Myeloid Leukemia (AML) in Finland and Spain.
Help employers find you! Check out all the jobs and post your resume.
comments powered by